Pharvaris (PHVS) AI Stock Analysis

• Market Cap: $1.27B
• Dividend Yield: N/A
• Average Volume (3M): 141.34K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.60
• Revenue Growth: N/A
• EPS Growth: 0.71%
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 64,055,640
• 10 Day Avg. Volume: 296,853
• 30 Day Avg. Volume: 141,337
• PEG Ratio: 0.39
• Price to Book (P/B): 3.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $34.25
• Price Target Upside: 72.28% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 42 Neutral
• Price Target: ―

Pharvaris exhibits significant financial difficulties, with no revenue and ongoing losses, resulting in a low financial performance score. Despite some technical momentum, the valuation is poor due to negative earnings. The stock's overall score is affected by these financial and valuation challenges, despite its technical strength.

Positive Factors

Efficacy Potential

Encouragement is drawn from the update, continuing to see deucrictibant delivering 'injection-like' efficacy across the on-demand and prophylactic treatment.

Financial Position

With a strong balance sheet and significant catalysts expected, analysts continue to hold a favorable view of the PHVS story.

Study Progress

Target enrollment in the RAPIDe-3 study was reached earlier this year, indicating strong progress in the study.

Negative Factors

Competitive Positioning

Analyst maintains an Underperform rating with a $14 price objective, indicating concerns about PHVS's competitive positioning in the HAE market.

Market Competition

Ekterly, recently approved as the first oral on-demand HAE therapy, will have at least 12 months of market exclusivity before PHVS can enter the market.

Market Dynamics

KalVista received FDA approval for Ekterly, the first oral on-demand treatment for hereditary angioedema, which may impact Pharvaris's market dynamics.

Pharvaris Business Overview & Revenue Model

Company Description

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

How the Company Makes Money

Pharvaris makes money by developing and commercializing oral therapies, primarily focusing on hereditary angioedema (HAE). As a clinical-stage company, its revenue model is dependent on advancing its drug candidates through clinical trials and eventually obtaining regulatory approval for commercial sale. Revenue streams are expected to come from potential future sales of approved therapies, licensing agreements, and partnerships with other pharmaceutical companies. Significant partnerships could involve collaboration on research and development, co-marketing, or distribution agreements that enhance the company's ability to bring its therapies to market.

Pharvaris Financial Statement Overview

Summary

Pharvaris faces significant financial challenges with no revenue generation and ongoing losses impacting income statements. The strong equity position provides some balance sheet stability, yet cash flow concerns remain due to negative operating and free cash flow, despite substantial financing inflows. The lack of revenue growth and profitability highlights the risks associated with the company's financial health.

Income Statement

Pharvaris has consistently shown no revenue generation over the years, leading to a lack of gross profit and persistent net losses. The company's net profit margin is nonexistent due to zero revenue, and the EBIT margin indicates significant operational losses. The financials reflect a challenging position in terms of profitability and revenue growth.

Balance Sheet

The balance sheet reveals a strong equity position with a high equity ratio, indicating stability and low financial leverage. The debt-to-equity ratio is minimal, suggesting limited reliance on debt. However, the company is not yet profitable, which poses a risk to long-term sustainability despite the strong equity base.

Cash Flow

Pharvaris has been experiencing negative free cash flow and operating cash flow, reflecting cash outflows that exceed inflows. The cash flow to net income ratios are not favorable due to persistent losses, indicating cash burn concerns. However, significant financing activities have bolstered cash reserves, providing some liquidity cushion.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-252.27K	-150.19K	-80.46K	0.00
EBITDA	-145.59M	-96.85M	-86.58M	-54.06M	-25.01M
Net Income	-134.22M	-100.88M	-76.33M	-42.73M	-25.99M
Balance Sheet
Total Assets	291.37M	398.69M	167.73M	212.09M	101.10M
Cash, Cash Equivalents and Short-Term Investments	280.73M	391.23M	161.84M	209.35M	98.63M
Total Debt	861.47K	238.91K	436.82K	250.18K	0.00
Total Liabilities	23.61M	14.65M	18.47M	7.14M	5.31M
Stockholders Equity	267.76M	384.05M	149.26M	204.95M	95.79M
Cash Flow
Free Cash Flow	-120.67M	-93.14M	-67.29M	-44.73M	-21.54M
Operating Cash Flow	-120.13M	-93.05M	-67.16M	-44.60M	-21.50M
Investing Cash Flow	-538.09K	-89.98K	-124.30K	-130.03K	-42.98K
Financing Cash Flow	2.68M	325.39M	8.65M	143.67M	101.20M

Pharvaris Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 19.88
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHVS, the sentiment is Neutral. The current price of 19.88 is below the 20-day moving average (MA) of 21.13, above the 50-day MA of 18.63, and above the 200-day MA of 18.21, indicating a neutral trend. The MACD of 0.44 indicates Positive momentum. The RSI at 48.45 is Neutral, neither overbought nor oversold. The STOCH value of 10.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PHVS.

Pharvaris Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVAC	76 Outperform	$1.21B	5.94	34.46%	―	799.36%	―
Sector *	65 Neutral	¥354.97B	10.64	-2.99%	2.47%	11.68%	-10.27%
XERS	65 Neutral	$815.19M	―	222.83%	―	29.88%	35.11%
ABCL	59 Neutral	$1.33B	―	-15.59%	―	-35.41%	-12.26%
XNCR	49 Neutral	$592.14M	―	-33.48%	―	-25.88%	-29.16%
ZYME	47 Neutral	$882.38M	―	-29.80%	―	85.05%	15.96%
PHVS	42 Neutral	$1.27B	―	-51.85%	―	―	0.71%